Jon Clardy
Corporate Officer/Principal at The Broad Institute, Inc.
Jon Clardy active positions
Companies | Position | Start |
---|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Jon Clardy